Found 9 results for Non-Small Cell Lung Cancer
A listing of Non-Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer
T
Tim Lautenschlaeger
There has been evidence that patients being treated with chemoradiation for Non-Small Cell Lung Cancer (NSCLC) have experienced cardiac toxicities (heart damage). This study is exploring if testing patients hearts that have been diagnosed with NSCLC before and after treatment can help investigators decrease heart damage for patients in the …
Exploring Treatment Options After Lung Cancer Surgery
V
Vijaya L. Kakani, MD
Do you have non-small cell lung cancer (NSCLC) but the cancer was not fully removed by surgery? You may qualify for a study exploring treatment options for NSCLC.This research study is testing whether adding a medication called sacituzumab tirumotecan to pembrolizumab after surgery may help prevent non-small cell lung cancer …
Together for Tomorrow: Explore New Treatment Options for Lung Cancer
V
Vijaya L. Kakani, MD
We understand that living with non-small cell lung cancer (NSCLC), especially with the KRAS G12C mutation, can be incredibly challenging. Many people with lung cancer go through hard treatments and tough side effects. That's why we're inviting adults (ages 18 and older) who have advanced or metastatic nonsquamous NSCLC to participate …
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
N
Nasser Hanna, MD
This research aims to incorporate ctDNA analysis into clinical practice to individualize therapy in patients with stage III NSCLC by moving to a treatment-by-marker based approach (as opposed to treatment based on clinical or radiographic evidence of disease). Interested in participating? For more information about this research study or other cancer-related …
A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of Tng462 in Combination with Other Agents in Patients with Pancreatic or Non-Small Cell Lung Cancer with Mtap Loss and Ras Mutation
A
Anita Turk, MD
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with the following agents: RMC-6236, RMC-9805, mFOLFIRINOX, or gemcitabine/nab-paclitaxel. Overall, the study comprises a dose escalation phase and a dose expansion phase.Interested in participating? For …
A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
R
Rohan Maniar
What is the purpose of this study?This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC …
A Randomized Phase Ii/Iii Study of Docetaxel and Ramucirumab with or Without Cemiplimab (Regn2810) for Participants Previously Treated with Platinum-Based Chemotherapy and Immunotherapy for Stage Iv or Recurrent Non-Small Cell Lung Cancer (Lung-Map Non-Matched Sub-Study)
R
Rohan Maniar
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody …
A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early Stage Non Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (Insight)
R
Rohan Maniar
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells …
DxB-062-NSCLC: Collection of fresh blood from treatment naive or progressing Stage IV m1b NSCLC cancer patients.
V
Vijay Khatri
The purpose of this study is to collect fresh blood from treatment naive or progressing Stage IV M1b Non-Small Cell Lung cancer (NSCLC) patients for research and development purposes.If the patient is a potential subject the provider will discuss with patient and provide an informed consent for more information. THIS STUDY …
Please choose between Voice or SMS based delivery of verification code
or